COX-2 inhibitors in prostate cancer treatment—hold your horses?

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2012,（4）
• 页码范围: 518-519
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2012.51

摘要

Cydo-oxygenase has been implicated as a potential therapeutic target in prostate cancer.However,the ongoing multi-arm randomized controlled STAMPEDE trial has failed to show a benefit of the cyclo-oxygenase 2 inhibitor celecoxib in men with locally advanced or metastatic prostate cancer also receiving androgen deprivation therapy.STAMPEDE uses a novel adaptive design that allows testing of different therapeutic interventions,and should generate much needed novel information regarding evidence-based prostate cancer management.